Bal Raj Bhandari

Statistics

Publications

Citations

2.5K

H-Index

Active since

2013

Affiliations

Delta Air Lines (United States)(Current)

Gilead Sciences (United States)

University of California San Diego

Lake Research Partners

Gastro One (United States)

Bal Raj Bhandari is an author at Delta Air Lines (United States) specializing in pharmacotherapy, pharmacology, and inflammatory bowel disease therapy.

Publications per year

2013–2023

Publications

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari et al. · New England Journal of Medicine · 2014 · 695 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley et al. · Hepatology · 2020 · 278 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Ira M. Jacobson, Eric Lawitz, Edward Gane et al. · Gastroenterology · 2017 · 239 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +12

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

William J. Sandborn, Marc Ferrante, Bal Raj Bhandari et al. · Gastroenterology · 2019 · 221 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 16